Due to the local infiltrating character of SRC, chemoradiotherapy could potentially have a positive effect in these patients as adjunctive locoregional treatment prior to surgery.4 In their study, Bleaney et al.10 concluded that patients with adenocarcinomas with SRC differentiation have a different response to neoadjuvant therapy than non-SRC adenocarcinomas, but the exact impact of SRC differentiation on neoadjuvant treatment and prognosis in esophageal adenocarcinomas remains unclear. The gene discussed is SRC; the disease is adenocarcinoma.